Hearing aid market in US grew by 37 percent in 2021

Hearing aid manufacturers have had a good year following one of the worst in their recorded history, as sales in the US have gone up by 37 percent. The progress is mainly driven by the recovery of independent retailers, whereas public sales channel Veterans Affairs still lags behind.

The year 2020 was written into history as a true annus horribilis for hearing aid manufacturers, whose primary customer segment comprises of the oldest part of the population, who largely kept away from audiologist appointments because of the Covid-19 pandemic.

2021 has turned out differently – at least on the private hearing aid market in the US, which is the world’s biggest single market, where sales of hearing aids went up by 37 percent compared to the year before, which was calculated from a total of 4.73 million units sold in 2021.

The figures have been gathered by industry association Hearing Industries Association (HIA), whose members include all of the world’s biggest hearing aid manufacturers. The comparison is based on a historically easy foundation, as hearing aid sales fell by 18 percent in the full year of 2020, with the second quarter of the year experiencing a dramatic decline in unit sales of 58.6 percent.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

In a world of options, Genmab's CEO chose partnerships

In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.

Analyst predicts slow start for Leo Pharma's Adtralza in UK

The take-up of Leo Pharma’s atopic eczema drug Adtralza in the UK will be slow-going, according to analyst bureau Global Data, after the British institute NICE released draft guidance where it was not recommend it as a standard treatment in England and Wales.

Further reading

Related articles

Latest news

See all jobs